Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Exp Hematol Oncol. 2024 Oct 26;13(1):104. doi: 10.1186/s40164-024-00577-5. ABSTRACT BACKGROUND: Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated promising clinical efficacy in B-cell malignancies, …